Salute e Benessere

Less Than 38% of Saudis Had Colorectal Cancer Screening

CRC Screening Gaps Vary Globally: A significant 49.3% of global respondents never had a CRC screening test, Saudi Arabia (62.0%) with the highest proportion. In addition, 39.7% Saudis believe there's not enough information available to assess their own CRC risk. CRC Screening Gaps Vary Globally : A significant 49.3% of global respondents never had a CRC screening test,Saudi Arabia(62.0%) with the highest proportion. In addition, 39.7% Saudis believe there's not enough information available...
PR Newswire
31/05/2024

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC…

Nat Lenzo, MD, Nuclear Oncologist and General Internal Medicine Physician and lead recruiter onto the SELECT trial, commented, "We are encouraged by this rPFS result, which compares favourably to small molecule radioligand therapy (RLT) Phase I and II studies at similar stages of development[6]. This is a compelling signal of the potential efficacy of TLX591 in this heavily pre-treated population. The results further support the development of this candidate in an earlier mCRPC patient…
PR Newswire
31/05/2024

Novartis Phase III data confirm sustained efficacy and long-term safety of oral…

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52) 1 Remibrutinib, an oral Bruton's tyrosine kinase inhibitor, demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo 1 Novartis intends to submit remibrutinib for approval in chronic spontaneous urticaria (CSU) to global health authorities starting...
Nasdaq GlobeNewswire
31/05/2024

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First…

SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the fieldCAMBRIDGE, Mass...
Nasdaq GlobeNewswire
30/05/2024

Pharming Group provides update on ongoing regulatory review of leniolisib for…

Leiden , the Netherlands, May 30, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Nasdaq GlobeNewswire
30/05/2024

Endo Provides Select First-Quarter 2024 Financial Results for Endo International…

EIPFIRST-QUARTER FINANCIAL PERFORMANCE(in thousands) EIPFIRST-QUARTER FINANCIAL PERFORMANCE (in thousands) EIP CONSOLIDATED FINANCIAL RESULTSTotal revenues were$420 millionin first-quarter 2024, a decrease of 19% compared to$515 millionin first-quarter 2023. This decrease was primarily attributable to decreased revenues from the Generic Pharmaceuticals segment. Reported Net Loss in first-quarter 2024 was$154 millioncompared to reported Net Loss of$3 millionin...
PR Newswire
30/05/2024

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk presentation...
Nasdaq GlobeNewswire
30/05/2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option…

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initialin vitrotesting...
Nasdaq GlobeNewswire
30/05/2024

Calliditas partner STADA receives positive CHMP opinion recommending full…

"This is an important day for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that EMA now has issued a positive opinion," said Renee Aguiar-Lucander, CEO. "This is an important day for patients suffering from IgAN inEuropeas Kinpeygo represents the first ever fully approved medication…
PR Newswire
30/05/2024

Ipsen announces the launch of an employee shareholding plan

Ipsen announces the launch of an employee shareholding planPARIS, FRANCE, 30 May 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) today announced the launch of an employee shareholding plan. The fourth transaction in the last eight years aims to involve Ipsen's employees more closely, both in France and abroad, in the Group's development and performance. It will be launched in 23 countries.This plan, for employee only, will be carried out through the sale of existing shares reserved...
Nasdaq GlobeNewswire
30/05/2024

OSE Immunotherapeutics Provides Business and Corporate Update

OSE Immunotherapeutics Provides Business and Corporate UpdateThree pharmaceutical agreements signed during the last three months:New strategic partnership with AbbVie for OSE-230, a novel preclinical potential first-in-class program for the treatment of chronic inflammation.Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds already developed in immuno-oncology, now expected in Phase...
Nasdaq GlobeNewswire
30/05/2024

L'OCCITANE en Provence and CARBIOS present a PET bottle made from enzymatic…

L'OCCITANE en Provence and CARBIOS present a PET bottle made from enzymatic recycling, the result of a European circular economyCARBIOS, L'OCCITANE en Provence and Pinard Beauty Pack join forces to establish an efficient European value chain for PET circularityThe 100% biorecycled transparent bottle (from enzymatic recycling) will be on display at CARBIOS' booth D02 at “Edition Spéciale” by LuxePack, held 4-5 June at the Carreau du Temple in ParisA key step towards achieving...
Nasdaq GlobeNewswire
30/05/2024

Partnership with Key Opinion Leaders and successful trainings

Press release Ecully, May 30, 2024 – 6 p.m. SPINEWAY organizes surgical training sessionsin the use of ESP and KAPHORN implantsThe Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it trained nearly 30 spine surgeons in the use of its product lines during a series of sessions held in April and May.These surgeons from several countries (Thailand, Indonesia, Vietnam, Tunisia, Switzerland and France) were...
Nasdaq GlobeNewswire
30/05/2024

Cold Laser Therapy Market worth $161.3 Million by 2031: Coherent Market…

Market Dynamics : The growth of the Cold Laser Therapy Market is driven by the rising prevalence of musculoskeletal conditions and increasing popularity of non-invasive pain relief therapies. Cold laser therapy is a non-invasive treatment method that uses light to stimulate healing responses at the cellular level. It helps reduce inflammation and swelling and alleviates pain related to various musculoskeletal conditions such as tendonitis, carpal tunnel syndrome, and arthritis...
PR Newswire
30/05/2024

VNA & PACS Market to be Worth $6.50 Billion by 2031 - Exclusive Report by…

Vendor Neutral Archive (VNA) is a medical archive system that allows planning and managing the life cycle of the medical files stored on it, while Picture Archiving and Communication System (PACS) is the system that electronically stores images. Both VNA & PACS play an important part in medical image management for aiding diagnosis, comparing images between patients or within the same patient at different time points to assess the progress of the disease, and evaluating prognosis. Vendor...
PR Newswire
30/05/2024

EssilorLuxottica: Result of the payment of dividends in shares and record of the…

Result of the payment of dividends in shares and record of the corresponding capital increaseCharenton-le-Pont, France(May 30, 2024 – 4:30 pm)– The Annual General Meeting of EssilorLuxottica has decided to grant to the shareholders the option to receive their dividend in shares. The price for newly issued shares for the payment of the dividend has been set at Euro 180.12 per share. This price corresponds to 90% of the average of the opening prices quoted on Euronext Paris over the...
Nasdaq GlobeNewswire
30/05/2024

High Potency Drug Market worth USD 379.20 Billion by 2031 - Says InsightAce…

High potency drugs are a growing segment in the pharmaceutical industry, characterized by their powerful biological activity and specificity. These drugs are designed to have a significant therapeutic effect at very low doses, often measured in micrograms or nanograms. This unique property makes them particularly useful for treating severe and life-threatening conditions such as cancer, where the intent is to deliver precise and targeted treatment to minimize side effects. High potency drugs...
PR Newswire
30/05/2024

Global Surgical Pliers Market to Exhibit Growth at a CAGR of ~5% by 2030 |…

Key Takeaways from the Surgical Pliers Market Report Key Takeaways from the Surgical Pliers Market Report To read more about the latest highlights related to the surgical pliers market, get a snapshot of the key highlights entailed in theGlobal Surgical Pliers Market Report Surgical Pliers Overview Surgical pliers are indispensable tools in the medical field, designed with precision and functionality to assist surgeons in a myriad of procedures. These versatile instruments...
PR Newswire
30/05/2024

"Disrupt" introduces Disrupt Health Impact Fund with leading business groups in…

Ms. Jantanarak Tuekaew, Partner of Disrupt Health Impact Fund added that, "Thailand has been ranked among the top ten in terms of health security and medical tourism. This presents an opportune moment for both Thai and foreign entrepreneurs. Disrupt Health Impact Fund is committed to investing in five key areas: Self Care, Preventive Care, Silver Age, Holistic Wellness, and Smart Hospital. The fund also aims to be the gateway to Southeast Asia for DeepTech companies in the healthcare sector…
PR Newswire
30/05/2024

Presentation of the Congress of the European Academy of Allergy and Clinical…

VALENCIA, Spain, May30, 2024(GLOBE NEWSWIRE) -- Under the theme "Revolutionizing Patient Care through the Power of Data Science," the congress will highlight the crucial role of Allergy and Clinical Immunology in advancing personalised care, data science, and a holistic approach to health. Kindly be invited to the press conference presenting the Congress of the European Academy of Allergy and Clinical Immunology (EAACI), which will bring together the world's leading allergy and...
Nasdaq GlobeNewswire
30/05/2024

TOOsonix receives MDR CE Mark for its new oncology and dermatology device

The certification allows TOOsonix to sell its flagship product, System ONE-M™, across the European Economic Area. Treatment of skin cancer and skin diseases can now be conducted in ways never before possible, providing more patient-friendly treatment than traditional procedures. The certification allows TOOsonix to sell its flagship product, System ONE-M™, across the European Economic Area. Treatment of skin cancer and skin diseases can now be conducted in ways never before possible…
PR Newswire
30/05/2024

Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8…

In the US, Lidoderm® is marketed by TPU Pharma (subsidiary of TPU) and its authorized generic lidocaine patch 5% is marketed by Endo USA, Inc. It is also marketed as Versatis® in Europe and Latin America by Grünenthal GmbH. Our lidocaine patch 5% has been marketed by our partners worldwide and over 3.7 billion patches have been delivered to patients since its launch. "Although this has been a long journey, we are happy to see Lidoderm® receive approval in China, an important market for our…
PR Newswire
30/05/2024

The Lancet Publishes Results from World's Largest Coronary CT Registry Showing…

Key study findings include: Key study findings include: "TheORFANstudy is an expanding global registry which will include long-term clinical and outcome data for 250,000 patients from around the world, and we are very pleased to publish these initial results," said Keith Channon , MD, Professor of Cardiovascular Medicine at theUniversity of Oxford, Caristo's Chief Medical Officer, and co-author ofThe Lancetpublication. "Coronary inflammation is a crucial piece of the puzzle in...
PR Newswire
30/05/2024

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

Sanofi completes acquisition of Inhibrx, Inc.Paris, May 30, 2024.Sanofi announced today the completion ofits acquisition of Inhibrx, Inc. (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi's rare disease pipeline, underscoring the company's commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities.SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1...
Nasdaq GlobeNewswire
30/05/2024
Altri  Comunicati